Cargando…

Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management

The combination of glucagon-like peptide-1 (GLP-1) with other gut hormones including the glucose-dependent insulinotropic polypeptide (GIP) has been explored to complement and enhance further the GLP-1 effects on glycemia and weight loss. Tirzepatide is the first dual GLP-1/GIP receptor co-agonist w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sinha, Rachel, Papamargaritis, Dimitris, Sargeant, Jack A., Davies, Melanie J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society for the Study of Obesity 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088547/ https://www.ncbi.nlm.nih.gov/pubmed/36750526 http://dx.doi.org/10.7570/jomes22067

Ejemplares similares

Tirzepatide for type 2 diabetes
por: Anderson, Sarah L, et al.
Publicado: (2023)

Advent of tirzepatide: boon for diabetic and obese?
por: Bhusal, Amrit
Publicado: (2023)

Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis
por: Tang, Yan, et al.
Publicado: (2022)

Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective
por: De Block, Christophe, et al.
Publicado: (2022)

Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A bayesian network meta-analysis
por: Guan, Ruifang, et al.
Publicado: (2022)

The catcher in the gut: Tirzepatide, a dual incretin analog for the treatment of type 2 diabetes mellitus and obesity
por: Lempesis, Ioannis G., et al.
Publicado: (2022)

Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
por: Zhou, Qian, et al.
Publicado: (2023)

Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis
por: Dutta, Deep, et al.
Publicado: (2021)

Tirzepatide—Friend or Foe in Diabetic Cancer Patients?
por: Samuel, Samson Mathews, et al.
Publicado: (2022)

Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials
por: Bhagavathula, Akshaya Srikanth, et al.
Publicado: (2021)

Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond
por: Dutta, Palak, et al.
Publicado: (2023)

Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis
por: Zeng, Qingyue, et al.
Publicado: (2023)

Where Does Metformin Stand in Modern Day Management of Type 2 Diabetes?
por: Ahmad, Ehtasham, et al.
Publicado: (2020)

Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin
por: MacIsaac, Richard J., et al.
Publicado: (2023)

Generalizability of the SURPASS‐2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control
por: Chiu, Nicholas, et al.
Publicado: (2022)

The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
por: Min, Thinzar, et al.
Publicado: (2020)

The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome
por: Anala, Alekya Devi, et al.
Publicado: (2023)

Tirzepatide: Does the Evidence to Date Show Potential for the Treatment of Early Stage Type 2 Diabetes?
por: Razzaki, Tanzila S, et al.
Publicado: (2022)

Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
por: Chavda, Vivek P., et al.
Publicado: (2022)

Tirzepatide: A Systematic Update
por: Forzano, Imma, et al.
Publicado: (2022)

Comparing Efficacy and Safety of Different Doses of Tirzepatide for the Treatment of Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials
por: Khan, Zarghuna, et al.
Publicado: (2023)

The importance of physical activity in management of type 2 diabetes and COVID-19
por: Seidu, Samuel, et al.
Publicado: (2021)

Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
por: Gallwitz, Baptist
Publicado: (2022)

Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity
por: Quddos, Fatima, et al.
Publicado: (2023)

The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
por: Jung, Han Na, et al.
Publicado: (2022)

Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide
por: Boye, Kristina S., et al.
Publicado: (2023)

Tirzepatide and prevention of chronic kidney disease
por: Bosch, Catalina, et al.
Publicado: (2022)

Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes
por: Heise, Tim, et al.
Publicado: (2023)

Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes
por: Ma, Zijun, et al.
Publicado: (2023)

Weight loss efficiency and safety of tirzepatide: A Systematic review
por: Lin, Fei, et al.
Publicado: (2023)

Nonlinear association of BMI with all-cause and cardiovascular mortality in type 2 diabetes mellitus: a systematic review and meta-analysis of 414,587 participants in prospective studies
por: Zaccardi, Francesco, et al.
Publicado: (2016)

Exit Interviews Examining the Patient Experience in Clinical Trials of Tirzepatide for Treatment of Type 2 Diabetes
por: Matza, Louis S., et al.
Publicado: (2022)

A Phase 1 Multiple Dose Study of Tirzepatide in Chinese Patients with Type 2 Diabetes
por: Feng, Ping, et al.
Publicado: (2023)

Short-term cost-effectiveness analysis of tirzepatide for the treatment of type 2 diabetes in the United States
por: Zhang, Xiaotong, et al.
Publicado: (2023)

Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
por: Wang, Lijing
Publicado: (2022)

Adverse Events Related to Tirzepatide
por: Mishra, Rahul, et al.
Publicado: (2023)

Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy
por: Goldney, Jonathan, et al.
Publicado: (2023)

Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program
por: le Roux, Carel W., et al.
Publicado: (2022)

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
por: Karagiannis, Thomas, et al.
Publicado: (2022)

Optimal dose of tirzepatide for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis
por: Yu, Yunfeng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ik4c4h7j9eeq8bidlrcnct4jcd